- Home
- ATER vs MYNZ Comparison
ATER vs MYNZ Comparison
Compare ATER & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATER | MYNZ |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 8.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATER | MYNZ |
|---|---|---|
| Price | $0.91 | $1.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 216.1K | ★ 339.3K |
| Earning Date | 11-13-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $78,450,000.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.48 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.64 | $0.92 |
| 52 Week High | $3.50 | $8.20 |
Technical Indicators
Market Signals| Indicator | ATER | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 63.96 | 53.25 |
| Support Level | $0.64 | $1.08 |
| Resistance Level | $0.82 | $1.50 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 100.00 | 52.00 |
Price Performance
Historical ComparisonAbout ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.